Clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to restore immune balance and treat autoimmune and inflammatory diseases
Clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to restore immune balance and treat autoimmune and inflammatory diseases. Its lead candidate is being evaluated in Phase 1 studies for rheumatoid arthritis and hidradenitis suppurativa.